stockrowAxsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) Return on assets
Axsome Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −21.0%, up 8.1 percentage points from fiscal 2025 (−29.1%). Over the past ten years it has ranged from −121.6% (fiscal 2018) to −29.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −29.1% | 20.55 |
| FY2024 | −49.7% | 2.36 |
| FY2023 | −52.0% | 37.25 |
| FY2022 | −89.3% | 5.94 |
| FY2021 | −95.2% | (44.61) |
| FY2020 | −50.6% | 7.34 |
| FY2019 | −57.9% | 63.65 |
| FY2018 | −121.6% | (43.12) |
| FY2017 | −78.5% | (16.14) |
| FY2016 | −62.3% | (15.24) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 2.77% |
| ORKA Oruka Therapeutics, Inc. compare | −17.8% |
| IONS Ionis Pharmaceuticals, Inc. compare | −18.9% |
| AXSM Axsome Therapeutics, Inc. | −21.0% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| PRAX Praxis Precision Medicines, Inc. compare | −36.8% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −41.8% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −99.8% |
| ABVX Abivax SA Sponsored ADR compare | −137.7% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on AXSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement